Cell and Gene Outsourcing

  1. Mitigating Risk Through Product Characterization 7/17/2019

    In this webinar, multiple approaches to characterizing the physico-chemical and structural attributes of therapeutic mAbs is presented with a focus on how it influences the resulting biological activity.

  2. Purity As A Priority: Optimizing Safety Measures For rAAV Therapies 2/11/2025

    Watch to learn how rAAV vectors in gene therapy are addressing manufacturing impurities, risks to patient safety, and analytical methods for detection while aiding sponsors in regulatory compliance.

  3. Accelerate Your AAV Journey To IND And Beyond 6/26/2025

    Explore essential QC strategies in AAV gene therapy and learn how to address rcAAV detection, viral clearance per ICH Q5A, and impurity profiling using NGS to meet evolving regulatory demands.

  4. Selecting The Right CMO For Your Gene Therapy 5/15/2020

    Find out what criteria makes a great CMO partner and how to know if it is the right one for your gene therapy.

  5. A Faster, More Sensitive Approach To Virus Detection 2/13/2026

    Discover a faster, more sensitive approach to rodent virus detection that offers a targeted NGS workflow to help uncover contaminants traditional assays may miss.

  6. Optimizing Monoclonal Antibody Manufacturing For Commercial Success

    Strategically optimize your upstream and downstream processes and decrease the timeline from optimization to commercial manufacturing.

  7. Eliminate Risk From Your Viral Vector Tech Transfers 12/5/2025

    Explore strategies to simplify viral vector tech transfers, reduce risk, and maintain quality under tight timelines, as well as a case study that demonstrates how to streamline this critical process.

  8. Navigating The Road To Gene Therapy Commercialization 8/27/2020

    With increases in development and investments in the gene therapy field, companies will increasingly be looking at manufacturing and commercialization of their therapies. Road to commercialization goes through a series of process validation phases. In this webinar, we take a closer look at the road to commercialization and focus on addressing primary questions.

  9. The Blazar® Platform In A Minute 3/12/2021

    The Blazar® Rodent Panel from the BioReliance® portfolio can speed cell line characterization and bulk harvest lot release testing. This degenerate PCR-based method accelerates characterization by reducing timelines by up to 80% and replaces the use of animals.

  10. Characterizing AAV Encapsidated Nucleic Acid Sequences Using NGS 8/11/2023

    Here, we discuss the characterization of several representative AAV molecules using next-generation sequencing (NGS), including the sequencing process, bioinformatic analysis, and representative results.